Who We Are
Our goal is to facilitate the advancement of late-stage clinical assets where R&D budget constraints have delayed further development by providing a R&D risk-sharing approach to financing as well as the human resources to get products with significant commercial potential to the market. A risk-sharing collaboration approach to clinical development is an essential tool for Pharma / Biotech companies to improve their R&D productivity. The individuals involved in Nuvelution bring a unique understanding of the ideal way to structure these types of partnerships given their extensive industry experience. We are entering a new era of pharmaceutical innovation and the flexibility offered through our R&D risk-sharing collaborations and development expertise offers companies an important weapon to stay ahead of the competition.
Why Nuvelution
1. Senior Pharma executives who understand our partners' financial needs and can be trusted to provide oversight and execution of their clinical programs
2. The financial flexibility and resources to fund programs from $50 to $500 million
3. Provides custom solutions that fully meet the requirements of our partners when undertaking R&D risk-sharing collaborations
2. The financial flexibility and resources to fund programs from $50 to $500 million
3. Provides custom solutions that fully meet the requirements of our partners when undertaking R&D risk-sharing collaborations
- Leverage Nuvelution's resources to increase R&D output
- Have input into clinical trial design and execution
- Maintain commercialization rights
